Clinical trial
Clinical Trial Phase III, Parallel Group, Randomized, Placebo-controlled, Double-blind, Multicenter Study to Evaluate the Efficacy and Safety of Tocilizumab Administration in Patients With Moderate-to-severe or Sight-threatening Graves' Ophthalmopathy (GO), That Had Not Responded Adequately to Treatment With Intravenous Corticoid Pulses.
NCT01297699 is registered in ClinicalTrials.gov with Hospital Clinico Universitario de Santiago as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Clinical Trial Phase III, Parallel Group, Randomized, Placebo-controlled, Double-blind, Multicenter Study to Evaluate the Efficacy and Safety of Tocilizumab Administration in Patients With Moderate-to-severe or Sight-threatening Graves' Ophthalmopathy (GO), That Had Not Responded Adequately to Treatment With Intravenous Corticoid Pulses.
- Lead sponsor
- Hospital Clinico Universitario de Santiago
- Phase
- Phase 3
- Overall status
- Completed
- Start date
- March 31, 2012
- Completion date
- December 31, 2015
- Enrollment
- 32 (actual)
- Sites
- 9
Conditions
As the registry lists them; a condition with its own page is linked.
graves´ ophthalmopathy, thyroid associated ophthalmopathies, thyroid eye disease